Clinical trials: Non-Muscle Invasive Bladder Urothelial Carcinoma
Bladder Cancer
Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
Phase I: To determine the safety, toxicity and efficacy profiles of intravesically administered Abraxane at the Maximum Tolerated Dose.
- Trial name
- NCT00583349
- Testing
- Abraxane
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Columbia University
Infiltrating Bladder Urothelial Carcinoma
A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer
If radical cystectomy remains the standard of care for muscle invasive bladder cancer, consequences of this surgical procedure are often harsh.
- Trial name
- GETUGV04 (NCT01495676)
- Testing
- Radiation + cisplatin, Radiation + cisplatin + gemcitabine
- Where
- 12 sites in France
- Volunteers
- 69 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Bladder Cancer
Markers of Response to Intravesical Bladder Cancer Therapy
The goal of this laboratory research study is to see if researchers can predict whose cancer will stay in remission and whose will return in patients receiving treatment for bladder cancer.
- Trial name
- NCT01007058
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center